Becton Dickinson Cash Flow from Financial Activities 2012-2026 | BDX
Becton Dickinson annual/quarterly cash flow from financial activities history and growth rate from 2012 to 2026. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities
- Becton Dickinson cash flow from financial activities for the quarter ending March 31, 2026 was $-0.302B, a 84.34% decline year-over-year.
- Becton Dickinson cash flow from financial activities for the twelve months ending March 31, 2026 was $-8.694B, a 393.22% decline year-over-year.
- Becton Dickinson annual cash flow from financial activities for 2025 was $-3.617B, a 273.31% decline from 2024.
- Becton Dickinson annual cash flow from financial activities for 2024 was $2.087B, a 206.7% decline from 2023.
- Becton Dickinson annual cash flow from financial activities for 2023 was $-1.956B, a 165.76% increase from 2022.
|
Becton Dickinson Annual Cash Flow Financial (Millions of US $) |
|
|---|---|
| 2025 | $-3,617 |
| 2024 | $2,087 |
| 2023 | $-1,956 |
| 2022 | $-736 |
| 2021 | $-3,306 |
| 2020 | $22 |
| 2019 | $-3,223 |
| 2018 | $-58 |
| 2017 | $10,977 |
| 2016 | $-1,761 |
| 2015 | $6,190 |
| 2014 | $-807 |
| 2013 | $-968 |
| 2012 | $-370 |
| 2011 | $-714 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $43.913B | $21.840B |
| Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $106.025B | 23.03 |
| Cardinal Health (CAH) | United States | $50.715B | 22.43 |
| West Pharmaceutical Services (WST) | United States | $18.493B | 35.19 |
| Straumann Holding AG (SAUHY) | Switzerland | $16.902B | 0.00 |
| Cooper (COO) | United States | $13.894B | 16.52 |
| Align Technology (ALGN) | United States | $12.400B | 21.09 |
| Henry Schein (HSIC) | United States | $8.645B | 15.16 |
| Merit Medical Systems (MMSI) | United States | $4.072B | 19.84 |
| DENTSPLY SIRONA (XRAY) | United States | $2.339B | 7.36 |
| STAAR Surgical (STAA) | United States | $1.309B | 0.00 |
| CONMED (CNMD) | United States | $1.107B | 7.97 |
| Pro-Dex (PDEX) | United States | $0.165B | 19.65 |
| Lifevantage (LFVN) | United States | $0.053B | 5.46 |
| Axe Compute (AGPU) | United States | $0.022B | 0.00 |